DiagnosTear Advances UK Market Entry Through Commercial Collaboration with Hanson Medical
Vancouver, British Columbia--(Newsfile Corp. - February 20, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a developer of rapid point-of-care diagnostics for ophthalmic conditions, today announced that it has entered into a Letter of Intent ("LOI") with Hanson Instruments Ltd. (trading as Hanson Medical), a United Kingdom-based supplier of ophthalmic and optometric equipment, to exclusively explore a commercial partnership for the TeaRx™ dr
2026-02-20 5:00 PM EST | DiagnosTear Technologies Inc.
Jones Healthcare Group Wins Best of Show and Best in Class Honours at PAC Global Awards for Qube(TM) Eco
London, Ontario--(Newsfile Corp. - February 20, 2026) - As healthcare systems face increasing pressure to reduce waste and carbon impact, packaging innovation must deliver measurable results without compromising patient safety or pharmacy workflow. At the same time, environmental claims across industries are under greater scrutiny, with regulators, retailers and consumers demanding proof over promise. At the 2026 PAC Global Awards ceremony, held February 18-19 in Toronto, Jones Healthca
Healthcare and Hospitals, Pharmaceuticals, Health
2026-02-20 12:36 PM EST | Jones Healthcare Group
Edison Issues Report on Custodian Property Income REIT (CREI)
London, United Kingdom--(Newsfile Corp. - February 20, 2026) - Edison issues report on Custodian Property Income REIT (LSE: CREI) Custodian Property Income REIT (CREI) has completed the £36m corporate acquisition of a highly complementary, diversified family-owned portfolio (Grove Court Properties), which is its second such transaction in the past nine months. The acquisition has been financed by the issuance to the vendor of new CREI shares (75%) on an adjusted NAV for NAV basis a
Banking / Financial Services, Computer Hardware, Computer Software, Health
2026-02-20 10:29 AM EST | Edison Group
Neural Therapeutics Announces CSE Application to Acquire Full Ownership of Hanf.com, Shareholder Meeting, SIO Agreement Amendment and Concurrent Financing
Toronto, Ontario--(Newsfile Corp. - February 19, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") is pleased to announce that it has formally applied to the Canadian Securities Exchange (the "CSE") for approval to acquire the remaining 69.25% interest in CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CBD retailers. Ronnie Jaegermann, Chief Executive Officer of CWE, stated: "Hanf.com h
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-19 8:53 AM EST | Neural Therapeutics Inc.
Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894
King of Prussia, Pennsylvania--(Newsfile Corp. - February 19, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-02-19 7:00 AM EST | Phio Pharmaceuticals Corp.
Rejuvenate Muscle Health(TM) Nears 10,000 Points of Distribution as Major U.S. Retailer Expands Functional Beverage Breakout by 2,105 Stores
Burlington, Ontario--(Newsfile Corp. - February 19, 2026) - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC: MUSLF) (FSE: 93X) ("Promino" or the "Company") announced today that a major U.S. retail partner will expand Rejuvenate Muscle Health™ into an additional 2,105 stores, with rollout set for mid May 2026. The expansion pushes the total number of North American points of distribution very near 10,000 points of distribution, marking a significant milestone in scale for the fa
Food / Beverages, Sports, Health
2026-02-19 7:00 AM EST | Promino Nutritional Sciences, Inc.
Optimi Health schließt Psilocybin-Export nach Australien zur Behandlung therapieresistenter Depression ab
Vancouver, British Columbia--(Newsfile Corp. - Donnerstag, 19. Februar 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" oder das "Unternehmen"), ein von Health Canada lizenzierter Hersteller von psychedelischen Arzneimitteln in pharmazeutischer Qualität, gab heute den Export seiner nach GMP-Standards hergestellten natürlichen 5-mg-Psilocybin-Kapseln nach Australien bekannt. Diese werden zur Behandlung von Patientinnen und Patiente
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-19 2:00 AM EST | Optimi Health Corp.
Optimi Health Completes Psilocybin Export to Australia for Treatment Resistant Depression
Vancouver, British Columbia--(Newsfile Corp. - February 19, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical-grade psychedelic drug products, today announced the export of its GMP-manufactured natural 5 mg psilocybin capsules to Australia for the treatment of patients diagnosed with treatment-resistant depression (TRD) under Australia's Authorised Prescriber Scheme.
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-19 2:00 AM EST | Optimi Health Corp.
Relief AI Inc. Congratulates Johannes "Hansi" Lochner on Historic Gold Medal Victory at the Milano, Cortina Italy Olympics
Toronto, Ontario--(Newsfile Corp. - February 18, 2026) - Relief AI Inc. (the "Company "or "Relief AI Inc.") (www.reliefai.ca), Relief AI Inc. proudly congratulates German bobsleigh champion Johannes Lochner on capturing the gold medal at the Milano, Cortina Italy Olympics, leading a historic podium sweep for Germany with gold, silver, and bronze in the 2 man bobsleigh event, a remarkable display of excellence
Technology, Healthcare and Hospitals, Health
2026-02-18 10:05 AM EST | Relief AI Inc.
15,000 Professionals Take Part in Association for the Advancement of Medical Instrumentation
Arlington, Virginia--(Newsfile Corp. - February 18, 2026) - More than 15,000 health technology professionals and organizations are now leveraging the advantages of being a member of the Association for the Advancement of Medical Instrumentation (AAMI). This is a major milestone for the member organization's representation of the health technology field. AAMI recently crossed the threshold of 15,000 members throughout its co
2026-02-18 8:51 AM EST | Association for the Advancement of Medical Instrumentation
Izotropic Signs Letter Agreement for Regional Operations in Africa & the GCC
British Columbia and Sacramento, California--(Newsfile Corp. - February 18, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that it has entered into a Letter Agreement (the "Agreement") with a business group ("BG
2026-02-18 8:00 AM EST | Izotropic Corporation
Aleen Inc. Announces Development of Wellness AI Agents
Toronto, Ontario--(Newsfile Corp. - February 18, 2026) - Aleen Inc. (CSE: ALEN.U), a digital wellness company, announces the launch of internal development initiatives focused on wellness-oriented AI agents designed to support clearer and more intuitive interaction with wellness information. These AI agents are being developed as assistive tools to help users navigate their wellness data, locate documents, understand archive structures, and move through the system more efficientl
2026-02-18 8:00 AM EST | Aleen Inc.
Cheelcare Closes $1.0 Million Unsecured Note Financing
Markham, Ontario--(Newsfile Corp. - February 18, 2026) - Cheelcare Inc. (TSXV: CHER) ("Cheelcare" or the "Company"), a Canadian innovator in advanced mobility solutions, today announced that it has closed its previously-announced offering of 12% unsecured promissory notes (the "Notes") for aggregate gross proceeds of $1,000,000 (the "Offering"). The Offering was subscribed by Pathfinder Asset Management Ltd., which purchased $750,000 aggregate principal amount of Notes, and NameSilo Tec
2026-02-18 7:30 AM EST | Cheelcare Inc.
Cosmo to Participate in Upcoming Investor Conferences
Dublin, Ireland--(Newsfile Corp. - February 18, 2026) - Cosmo Pharmaceuticals N.V. (“Cosmo”) is pleased to announce its participation in the following upcoming investor conferences: UBS European Healthcare Conference 2026 London, United Kingdom 4 March 2026 Svetlana Sigalova, Chief Financial Officer, will participate in one-on-one meetings with investors.
Healthcare and Hospitals, Health
2026-02-18 1:01 AM EST | Cosmo Pharmaceuticals N.V.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - February 17, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the third quarter of fiscal year 2026, the three months ended December 31, 2025 ("Third Quarter"). Consolidated revenues for the three-month period ending December 31, 2025, were $31.6 million, an increase of $17.2 million or approximately 120% as compared
Healthcare and Hospitals, Pharmaceuticals, Health
2026-02-17 4:19 PM EST | Elite Pharmaceuticals, Inc.
Functional Brands Inc. Introduces Kirkman's(R) Exciting New Restorative Sleep Bundle for Deep, Refreshing Sleep Without Grogginess
Lake Oswego, Oregon--(Newsfile Corp. - February 17, 2026) - Functional Brands Inc. (NASDAQ: MEHA), a leading innovator in wellness and performance products, is thrilled to announce the launch of the new Kirkman® Restorative Sleep Bundle, a carefully formulated combination designed to promote deep, restorative sleep and calm the nervous system-without the morning grogginess commonly associated with sleep aids. The bundle features Herbal Sleep Aid (melatonin-free), GABA 25
Household / Consumer / Cosmetics, Health
2026-02-17 8:00 AM EST | Functional Brands Inc.
Safe Supply Announces Sale of Two NIRLAB Drug Analysis Devices Supporting Indigenous-Led Community Safety Initiatives
Toronto, Ontario--(Newsfile Corp. - February 17, 2026) - Safe Supply Streaming Co Ltd. (CSE: SPLY) (OTCQB: SSPLF) (FSE: QM4) ("Safe Supply" or the "Company") today announced the sale of two NIRLAB SA ("NIRLAB") drug analysis devices to a First Nation community to support local safety, health, and emergency-response initiatives. The deployment of two additional NIRLAB devices expands access to rapid, field-deployable drug identification technology within Indi
2026-02-17 7:12 AM EST | Safe Supply Streaming Co Ltd.
Optimi Health Reports First MDMA-Assisted Treatments of 2026 are Underway Across an Expanded Network of Australian Clinics
Vancouver, British Columbia--(Newsfile Corp. - February 17, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug products, today reported that the first patients of 2026 have been treated using the Company's MDMA capsules at authorised clinics across Australia, operating under the Authorised Prescriber Scheme. The Company continues to supply its finished MDMA drug product d
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-17 7:00 AM EST | Optimi Health Corp.
QScreen AI Advances Quantum-Inspired Optimization with U.S. Patent Filing; Gains National Spotlight on CBC
Toronto, Ontario--(Newsfile Corp. - February 17, 2026) - QScreen AI Inc (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP), an innovator fusing Quantum-AI technologies to transform health screening and employee wellness, today announced the filing of a provisional patent application with the United States Patent and Trademark Office (USPTO). Entitled "System, Method, and Robotic Platform for Quantum-Inspired Multi-Objective Optimization of Human-Governed Clinical Intake and Readiness Data Collection Und
2026-02-17 7:00 AM EST | QScreen AI Inc.
Adia Nutrition Announces Subsidiary Adia Med's Submission of Second Clinical Study for IRB Review Targeting Lower Back Pain with AdiaVita
Winter Park, Florida--(Newsfile Corp. - February 16, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine and innovative therapeutic solutions, today announced that its subsidiary, Adia Med of Winter Park, LLC, has submitted its second clinical study for Institutional Review Board (IRB) review. This pivotal study will evaluate the efficacy of AdiaVita, Adia Med's proprietary umbilical cord blood-derived stem cell and exosome product, in alleviating lower back pain thro
Healthcare and Hospitals, Health
2026-02-16 9:00 AM EST | Adia Nutrition Inc.